SBIR/STTR Research Award

Development of high-throughput cardiotoxicity and hepatotoxicity assays with magnetic 3D bioprinting

Award identifier 753829de6c6aa531265c19713cbb3854c78495dc8794116bc4e6f860e5ae0fe9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$999,999

Program and phase

SBIR · Phase II

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CHEMOSEN3D INC
Proposal award date
2016-08-01
Contract end date
2019-07-31
UEI
LH32V6UMM1K5
Solicitation number
PA15-269
Topic code
113

Research abstract

PROJECT SUMMARYThe goal of this proposal is to develop assays for cardiotoxicity and hepatotoxicity using magneticD bioprintingBoth cardiotoxicity and hepatotoxicity are critical areas for safety testingand in need of more accurate in vitro screens to prevent costly market withdrawalsHowevercurrent in vitro options are lacking in throughput and representation of native tissue environmentsThis proposal uses magneticD bioprinting to createD in vitro culture models that mimic native tissueThe principle behind magneticD bioprinting is the magnetization of cells and their printing using magnetic forcesThis method is rapid and easy to useand escapes the technical issue of otherD culture models that limit its use for high throughput screeningIn Phase Ia general toxicity assaythe BiO Assaywas developed using magneticallyD bioprinted spheroidsThis Phase II builds on that successby developing this cytotoxic assay for cardiomyocytes and hepatocytesthen further developing tissue specific functional assays to determine the effect of compounds on tissue functionFor cardiomyocytesa beating assay will be developed to assay a compound s effect on beatingwhile for hepatocytesan assay for cytochrome Pinduction inhibition will be developed to assay a compound s effect on metabolismIn combination with other assayssuch as LC MS and fluorescent calcium signaling assaysour assays will offer high content and high throughput solutions to study both cytotoxicity and functional toxicityThis work aids NIEHS in its goal of finding in vitro solutions for toxicity screening that are high throughput and representative of native tissue environmentsThe end result of this proposed work is a full suite of assays to study a compound s cardiotoxic and hepatotoxic effects

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2010–2018). Reported award amounts total $2,215,805. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.